Caris Life Sciences successfully priced its initial public offering at $21 per share, raising nearly $494 million to expand its molecular profiling services for cancer. Leveraging next-generation sequencing and AI, Caris has amassed a vast clinico-genomic database from millions of tests, aiding early detection and therapy selection. The firm’s FDA-cleared MI Cancer Seek assay and blood-based Caris Assure test are key commercial drivers. Partnerships with biopharma and academic centers bolster research and personalized treatment strategies, aiming to improve patient outcomes through advanced precision diagnostics.